GlassScriptPhysician profile
Ricardo Longarini
NPI 1285618421
$2,326.03
in general payments reported to CMS, 2019-2025
18 companies · $15.33 in 2025
The $15.33 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15.40 · 2020: $250 · 2021: $528 · 2022: $417 · 2023: $634 · 2024: $466 · 2025: $15.33.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,115.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $697.19 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $547.00 | 2020-2025 | Eliquis, Camzyos |
| Astrazeneca Pharmaceuticals LP | $190.09 | 2021-2024 | Farxiga |
| Alexion Pharmaceuticals, INC. | $178.23 | 2021-2024 | Soliris, Ultomiris |
| Abbvie INC. | $145.38 | 2023 | |
| Pfizer INC. | $138.62 | 2022-2024 | |
| Aimmune Therapeutics, INC. | $65.86 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.56 | 2023 | Jardiance |
| La Jolla Pharmaceutical Company | $54.22 | 2024 | Giapreza |
| Shionogi INC | $52.95 | 2021-2022 | |
| Daiichi Sankyo INC. | $35.62 | 2021 | |
| Novartis Pharmaceuticals Corporation | $35.33 | 2020-2021 | |
| Gilead Sciences, INC. | $27.53 | 2023 | Veklury |
| Vapotherm INC | $25.27 | 2021 | |
| Merck Sharp & Dohme LLC | $21.80 | 2024 | Recarbrio, Zerbaxa, Dificid |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Melinta Therapeutics, LLC | $20.00 | 2022 | |
| Tactile Systems Technology INC | $18.75 | 2023 | Flexitouch Plus, Entre Plus |
| Sanofi-Aventis U.S. LLC | $15.63 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ricardo Longarini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.